Mutual of America Capital Management LLC Cuts Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Mutual of America Capital Management LLC reduced its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 7.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 46,431 shares of the biopharmaceutical company’s stock after selling 3,771 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Intra-Cellular Therapies were worth $3,213,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Neo Ivy Capital Management acquired a new position in Intra-Cellular Therapies in the third quarter worth about $45,000. American Century Companies Inc. lifted its holdings in Intra-Cellular Therapies by 5.1% in the third quarter. American Century Companies Inc. now owns 441,410 shares of the biopharmaceutical company’s stock worth $22,993,000 after acquiring an additional 21,604 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Intra-Cellular Therapies by 6.7% in the third quarter. Wellington Management Group LLP now owns 1,815,954 shares of the biopharmaceutical company’s stock worth $94,593,000 after acquiring an additional 114,370 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Intra-Cellular Therapies in the third quarter worth about $1,823,000. Finally, Teachers Retirement System of The State of Kentucky lifted its holdings in Intra-Cellular Therapies by 95.6% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 10,958 shares of the biopharmaceutical company’s stock worth $571,000 after acquiring an additional 5,355 shares during the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, Director Rory B. Riggs sold 4,462 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $75.57, for a total value of $337,193.34. Following the transaction, the director now owns 116,600 shares in the company, valued at $8,811,462. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Intra-Cellular Therapies news, Director Rory B. Riggs sold 4,462 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $75.57, for a total value of $337,193.34. Following the transaction, the director now owns 116,600 shares in the company, valued at $8,811,462. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Nostrand Robert L. Van sold 20,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $75.91, for a total transaction of $1,518,200.00. Following the completion of the transaction, the director now owns 9,690 shares in the company, valued at approximately $735,567.90. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI opened at $78.32 on Friday. Intra-Cellular Therapies, Inc. has a 12 month low of $45.50 and a 12 month high of $84.89. The firm has a market capitalization of $8.27 billion, a PE ratio of -67.52 and a beta of 1.01. The company’s 50 day simple moving average is $69.21 and its 200 day simple moving average is $69.38.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The business had revenue of $144.90 million for the quarter, compared to analyst estimates of $141.41 million. During the same quarter last year, the business earned ($0.46) earnings per share. The business’s revenue for the quarter was up 52.0% on a year-over-year basis. Sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Needham & Company LLC raised their target price on shares of Intra-Cellular Therapies from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Tuesday, June 18th. Canaccord Genuity Group raised their target price on shares of Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Mizuho lifted their price target on Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a report on Friday, June 21st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $103.00 price target on shares of Intra-Cellular Therapies in a report on Tuesday, June 25th. Finally, UBS Group reaffirmed a “neutral” rating and set a $83.00 price target (down previously from $85.00) on shares of Intra-Cellular Therapies in a report on Tuesday, June 25th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.33.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.